# Nuclide record prince-trial (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/prince-trial/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "prince-trial", "NCT03658447" ;
  schema:name "PRINCE"@en ;
  schema:alternateName "PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr"@en ;
  schema:description "Combining the radioactive drug lutetium-PSMA with the immunotherapy drug pembrolizumab produced strong PSA responses in men with advanced, heavily pretreated prostate cancer, with side effects in line with what each drug causes on its own."@en ;
  schema:url <https://nuclide.cc/trials/prince-trial/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/41926961/>, <https://clinicaltrials.gov/study/NCT03658447> ;
  nuclide:status "completed" ;
  nuclide:tag "radioligand therapy", "prostate cancer", "immunotherapy combination" ;
  nuclide:phase "1/2" ;
  nuclide:related <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/pembrolizumab/>, <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/trials/vision/>, <https://nuclide.cc/isotopes/lu-177/> .